Original Article

Diagnostic Accuracy and Chromosomal Microarray and Karyotype Analysis with Different Clinical Biomarkers for Prenatal Diagnosis of Fetal Genetic Diseases

Abstract

Background: We compared the diagnostic accuracy and application value of chromosome microarray (CMA) technique and karyotype analysis for prenatal diagnosis of fetal genetic diseases using different clinical markers.
Methods: This is a prospective clinical study involving 1587 pregnant women who underwent amniocentesis for prenatal diagnosis due to various abnormal clinical indications in China between May 2018 and Nov 2021. Both chromosome microarray and karyotype analysis were applied. Participants were categorized into six groups based on different indications for prenatal diagnosis. The detection rates of chromosome microarray and karyotype analysis were compared. The study utilized SPSS version 20 for data analysis, employing descriptive statistics for count data results and chi-square statistics for statistical associations between outcomes and predictors.
Results: Chromosome microarray and karyotype analysis detected more abnormal chromosomes in the group with abnormal NIPT, with positive detection rates of 59.68% and the group in other situation with positive detection rates of 39.22%. Overall, 343 chromosome abnormalities were detected among participants. Overall, 101 cases chose induced labor, 240 cases gave birth, 1 newborn died after delivery, 1 case of twin chose selective reduction, another fetus gave birth, and 1 case lost to follow-up. The detection rate of chromosome abnormality in high-risk population was more than 1/5, highlighting the importance of reducing the incidence of birth defects through interventional prenatal diagnosis.
Conclusion: Clinically, Down's screening, NIPT and prenatal ultrasound screening can be conducted initially, followed by karyotype analysis and CMA detection for those with abnormal findings.

1. Montazerinezhad S, Emamjomeh A, Hajieghrari B (2020). Chromosomal ab-normality, laboratory techniques, tools and databases in molecular cytogenetics. Mol Biol Rep, 47(11): 9055–9073.
2. Chen CP (2007). Chromosomal abnormali-ties associated with neural tube defects (I): Full aneuploidy. Taiwan J Obstet Gyne-col, 46: 325–335.
3. Shan-shan L, Yan-fang Z, Feng-hua X, Dong-xiu L, Xiang H (2018). Clinical value of CMA and karyotype analysis in diagnosis of fetal chromosomal abnor-malities. J Modern Lab Med, 126–129.
4. Lo YMD (2020). Screening of fetal chro-mosomal aneuploidy by noninvasive prenatal testing: From innovation to set-ting public health agendas to potential impact on other fields. Clin Chem, 66(1): 25–28.
5. Sun X, Lu J, Ma X (2019). An efficient method for noninvasive prenatal diag-nosis of fetal trisomy 13, trisomy 18, and trisomy 21. PLoS ONE, 14(4): e0215368.
6. Singh RK, Prasad DN, Bhardwaj TR (2015). Synthesis, physicochemical and kinetic studies of redox derivative of bis (2-chloroethylamine) as alkylating cytotox-ic agent for brain delivery. Arab J Chem-istry, 8(3): 380–387.
7. Lu S, Kakongoma N, Hu WS, et al. (2023). Detection rates of abnormalities in over 10,000 amniotic fluid samples at a single laboratory. BMC Pregnancy Childbirth, 23(1): 102.
8. Li Z, Di J (2021). Prevention and control of birth defects in China: Achievements and challenges. China CDC Weekly, 3: 771.
9. Howell KB, Eggers S, Dalziel K, et al (2018). A population-based cost-effectiveness study of early genetic test-ing in severe epilepsies of infancy. Epi-lepsia, 59(6): 1177–1187.
10. Vermeesch JR, Voet T, Devriendt K (2016). Prenatal and pre-implantation genetic diagnosis. Nat Rev Genet, 17(10): 643-56.
11. Huang H, Wang Y, Zhang M, et al (2021). Diagnostic accuracy and value of chro-mosomal microarray analysis for chro-mosomal abnormalities in prenatal de-tection: A prospective clinical study. Medicine (Baltimore), 100(20): e25999.
12. Miller DT, Adam MP, Aradhya S, et al (2010). Consensus statement: chromo-somal microarray is a first-tier clinical diagnostic test for individuals with de-velopmental disabilities or congenital anomalies. Am J Hum Genet, 86(5): 749–764.
13. Li L, Zhang H, Yang Y, et al (2020). High frequency of Y chromosome microdele-tions in male infertility patients with 45,X/46,XY mosaicism. Braz J Med Biol Res, 53(3): e9021.
14. Li W, Lu-Sha D, Xiao-Dan Z (2018). Appli-cation of chromosomal microarray analysis in prenatal diagnosis. Matern Child Health Care China, 139–141.
15. Levy B, Wapner R (2018). Prenatal diagno-sis by chromosomal microarray analy-sis. Fertil Steril, 109(2): 201–212.
16. Subspecialty Group of Clinical Genetics et al (2016). Expert consensus on the clini-cal application of chromosome genome chips in pediatric genetic diseases. Zhonghua Er Ke Za Zhi, 54(6):410-3.
17. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA (1994). Reducing the need for amniocen-tesis in women 35 years of age or older with serum markers for screening. N Engl J Med, 330(16): 1114–1118.
18. Dharajiya N, Zwiefelhofer T, Guan X, Angkachatchai V, Saldivar JS (2015). Noninvasive prenatal testing using cell-free fetal DNA in maternal plasma. Curr Protoc Hum Genet, 84:8.15.1–8.15.20.
19. Sahota DS, Leung WC, Chan WP, To WWK, Lau ET, Leung TY (2013). Pro-spective assessment of the Hong Kong Hospital Authority universal Down syn-drome screening programme. Hong Kong Med J, 19(2): 101–108.
20. Iwarsson E, Jacobsson B, Dagerhamn J, et al (2017). Analysis of cell-free fetal DNA in maternal blood for detection of tri-somy 21, 18 and 13 in a general preg-nant population and in a high-risk popu-lation – a systematic review and meta-analysis. Acta Obstet Gynecol Scand, 96(1): 7–18.
21. Liu Y, Liu H, He Y, et al (2020). Clinical performance of non-invasive prenatal testing as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China. Hum Genomics, 14(1): 21.
22. Jayashankar SS, Nasaruddin ML, Hassan MF, et al (2023). Non-invasive prenatal testing (NIPT): Reliability, challenges, and future directions. Diagnostics (Basel), 13(15): 2570.
23. van der Meij KR, Sistermans EA, Macville MV, et al. (2019). TRIDENT-2: National implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in the Netherlands. Am J Hum Genet, 105(6): 1091–1101.
24. Uzman A, Lodish H, Berk A, Zipursky L, Baltimore D (2000). Molecular Cell Biology. 4th ed. W. H. Freeman and Company, New York, NY, pp.: Section 1.2 – The Molecules of Life.
25. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010). Is the incidence of rheumatoid arthritis ris-ing?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum, 62(6): 1576–1582.
Files
IssueVol 54 No 5 (2025) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v54i5.18634
Keywords
Chromosome abnormality Chromosome microarray analysis Karyotype analysis Prenatal diagnosis Noninvasive screening
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Cai F, Shen R, Wang H, Zheng Y, Zhang W, Jin L. Diagnostic Accuracy and Chromosomal Microarray and Karyotype Analysis with Different Clinical Biomarkers for Prenatal Diagnosis of Fetal Genetic Diseases. Iran J Public Health. 2025;54(5):992-1002.